Use of 3′-deoxy-3′-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 4, 2006, Pages 412-419

  Yang, You Jung ^a   Ryu, Jin Sook ^a   Kim, Seog Young ^a   Seung, Jun Oh ^a   Ki, Chun Im ^a   Lee, Heuiran ^a   Lee, Sang Wook ^a   Kyung, Ja Cho ^a   Cheon, Gi Jeong ^b   Dae, Hyuk Moon ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

18F fluorodeoxyglucose; 18F fluorothymidine; Positron emission tomography; Radiotherapy; Small animal imaging

Indexed keywords

3' FLUOROTHYMIDINE F 18; 4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; FLUORODEOXYGLUCOSE F 18; HOE 33342; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG UPTAKE; HISTOPATHOLOGY; MALE; MORPHOLOGY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; SQUAMOUS CELL CARCINOMA; STAINING; TUMOR GROWTH; ANIMAL; C3H MOUSE; CELL PROLIFERATION; METHODOLOGY; PROGNOSIS; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; MALE; MICE; MICE, INBRED C3H; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 33645856494     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-0011-4     Document Type: Article

References (43)

1. Van de Wiele C, Lahorte C, Oyen W, Boerman O, Goethals I, Siegers G, et al. Nuclear medicine imaging to predict response to radiotherapy: a review. Int J Radiat Oncol Biol Phys 2003;55:5-15
2. Avril NE, Weber WA. Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am 2005;43:189-204
3. Fornace A FZ, Weichselbaum RR, Milas L. Radiation therapy. In. Mendelsohn J, Howley PM, Israel MA, Liotta LA, editors. The molecular basis of cancer. Philadelphia: Saunders; 2001; p. 423-54
4. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16
5. Hicks RJ, MacManus MP, Matthews JP, Hogg A, Binns D, Rischin D, et al. Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 2004;60:412-8
6. Erdi YE, Macapinlac H, Rosenzweig KE, Humm JL, Larson SM, Erdi AK, et al. Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 2000;27:861-6
7. 18FDG-PET. Oral Oncol 2005;41:390-5
8. 18F-FDG PET early after radiotherapy in lymphoma patients. Cancer Biother Radiopharm 2004;19:606-12
9. Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin North Am 2005;43:153-67
10. Lonneux M, Sibomana M, Pauwels S, Gregoire V. Current data and perspectives on positron emission tomography oncology-radiotherapy [in French]. Cancer Radiother 1999;3:275-88
11. Lowe V. PET and PET-CT in oncology. Berlin Heidelberg New York: Springer; 2003; p. 303-8
12. Hautzel H, Muller-Gartner HW. Early changes in fluorine-18-FDG uptake during radiotherapy. J Nucl Med 1997;38:1384-6
13. 11C labeled thymidine for tumor visualization using positron emission tomography. Int J Appl Radiat Isot 1984;35:705-8
14. 11C)thymidine. Proc Natl Acad Sci U S A 1972; 69:988-92
15. 11C]thymidine for quantification of cellular proliferation with PET. Int J Rad Appl Instrum [A] 1991;42:103-4
16. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4:1334-6
17. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002;43:1210-7
18. 3H] arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol 2002;29:281-7
19. He Q, Skog S, Welander I, Tribukait B. X-irradiation effects on thymidine kinase (TK): I. TK1 and 2 in normal and malignant cells. Cell Prolif 2002;35:69-81
20. Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Effect of p53 activation on cell growth, thymidine kinase-1 activity, and 3′-deoxy-3′fluorothymidine uptake. Nucl Med Biol 2004;31:419-23
21. 18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med 2004;45:1754-8
22. 18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 2002;29:1462-9
23. 18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003;63:3791-8
24. 18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 2005;65:4202-10
25. 18F-fluorothymidine PET. J Nucl Med 2005;46:114-20
26. 18F] fluorothymidine. Nucl Med Biol 2004;31:803-9
27. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000;408:433-9
28. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001;27:247-54
29. Little JB. Delayed initiation of DNA synthesis in irradiated human diploid cells. Nature 1968;218:1064-5
30. Munch-Petersen B, Cloos L, Jensen HK, Tyrsted G. Human thymidine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul 1995;35:69-89
31. Coloma J, Castell JV. Isozyme pattern of thymidine kinase during liver regeneration. Hoppe Seylers Z Physiol Chem 1984;365:457-62
32. Ellims PH, Van der Weyden MB, Medley G. Thymidine kinase isoenzymes in human malignant lymphoma. Cancer Res 1981;41:691-5
33. Sakamoto S, Iwama T, Tsukada K, Utsunomiya J, Kawasaki T, Okamoto R. Increased activity of thymidine kinase isozyme in human colon tumor. Carcinogenesis 1984;5:183-5
34. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science 1996;274:1664-72
35. Lane DP. Cancer. p53, guardian of the genome. Nature 1992;358:15-6
36. Fei P, El-Deiry WS. P53 and radiation responses. Oncogene 2003;22:5774-83
37. Boothman DA, Davis TW, Sahijdak WM. Enhanced expression of thymidine kinase in human cells following ionizing radiation. Int J Radiat Oncol Biol Phys 1994;30:391-8
38. Kreder NC, van Bree C, Peters GJ, Loves WJ, Haveman J. Enhanced levels of deoxycytidine kinase and thymidine kinase 1 and 2 after pulsed low dose rate irradiation as an adaptive response to radiation. Oncol Rep 2002;9:141-4
39. Saito Y, Milross CG, Hittelman WN, Li D, Jibu T, Peters LJ, et al. Effect of radiation and paclitaxel on p53 expression in murine tumors sensitive or resistant to apoptosis induction. Int J Radiat Oncol Biol Phys 1997;38:623-31
40. 3H]thymidine, and gallium-67. J Nucl Med 1991; 32:2118-23
41. Furuta M, Hasegawa M, Hayakawa K, Yamakawa M, Ishikawa H, Nonaka T, et al. Rapid rise in FDG uptake in an irradiated human tumour xenograft. Eur J Nucl Med 1997;24:435-8
42. Weber G. Enzymology of cancer cells (second of two parts). N Engl J Med 1977;296:541-51
43. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987;235:1492-5